Greg C. Rigdon

1.8k total citations
39 papers, 1.5k citations indexed

About

Greg C. Rigdon is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Cognitive Neuroscience. According to data from OpenAlex, Greg C. Rigdon has authored 39 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Cellular and Molecular Neuroscience, 19 papers in Molecular Biology and 9 papers in Cognitive Neuroscience. Recurrent topics in Greg C. Rigdon's work include Neuroscience and Neuropharmacology Research (18 papers), Neurotransmitter Receptor Influence on Behavior (16 papers) and Ion channel regulation and function (6 papers). Greg C. Rigdon is often cited by papers focused on Neuroscience and Neuropharmacology Research (18 papers), Neurotransmitter Receptor Influence on Behavior (16 papers) and Ion channel regulation and function (6 papers). Greg C. Rigdon collaborates with scholars based in United States, United Kingdom and Netherlands. Greg C. Rigdon's co-authors include Mark H. Norman, Douglas J. Minick, James H. Pirch, Frank Navas, Robert W. McNutt, K J Chang, Alan D. Wickenden, Grant McNaughton‐Smith, Rosemarie Roeloffs and Barrett R. Cooper and has published in prestigious journals such as Blood, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Greg C. Rigdon

38 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Greg C. Rigdon United States	21	781	753	356	201	167	39	1.5k
C. Renault France	18	1.3k 1.7×	957 1.3×	194 0.5×	191 1.0×	84 0.5×	25	1.9k
C. Guérémy France	25	1.7k 2.2×	1.3k 1.7×	342 1.0×	265 1.3×	95 0.6×	51	2.6k
M.C. Dubroeucq France	18	1.4k 1.7×	925 1.2×	185 0.5×	220 1.1×	79 0.5×	24	2.0k
John L. Musachio United States	31	1.2k 1.6×	1.8k 2.4×	259 0.7×	152 0.8×	51 0.3×	80	3.0k
H. Donald Burns United States	23	554 0.7×	497 0.7×	102 0.3×	84 0.4×	70 0.4×	58	1.3k
Hiromi Sano Japan	26	770 1.0×	581 0.8×	341 1.0×	331 1.6×	27 0.2×	81	1.9k
Pierre Mallorga United States	19	932 1.2×	855 1.1×	164 0.5×	129 0.6×	34 0.2×	43	1.6k
M. Duff Davis United States	21	666 0.9×	615 0.8×	122 0.3×	114 0.6×	28 0.2×	51	1.2k
D. Duverger France	17	695 0.9×	486 0.6×	173 0.5×	102 0.5×	52 0.3×	24	1.6k
Eiji Mizuta Japan	21	457 0.6×	383 0.5×	184 0.5×	42 0.2×	56 0.3×	59	1.4k

Countries citing papers authored by Greg C. Rigdon

Since Specialization

Citations

This map shows the geographic impact of Greg C. Rigdon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg C. Rigdon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg C. Rigdon more than expected).

Fields of papers citing papers by Greg C. Rigdon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg C. Rigdon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg C. Rigdon. The network helps show where Greg C. Rigdon may publish in the future.

Co-authorship network of co-authors of Greg C. Rigdon

This figure shows the co-authorship network connecting the top 25 collaborators of Greg C. Rigdon. A scholar is included among the top collaborators of Greg C. Rigdon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg C. Rigdon. Greg C. Rigdon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Raskin, Joel, Anita H. Clayton, Susan G. Kornstein, et al.. (2025). A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder. Current Medical Research and Opinion. 41(9). 1723–1734.

Rigdon, Greg C., et al.. (2024). Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults. Clinical Pharmacology in Drug Development. 14(1). 18–25. 3 indexed citations

Aleo, Michael D., Jiri Aubrecht, Paul D. Bonin, et al.. (2019). Phase I study of PF‐04895162, a Kv7 channel opener, reveals unexpected hepatotoxicity in healthy subjects, but not rats or monkeys: clinical evidence of disrupted bile acid homeostasis. Pharmacology Research & Perspectives. 7(1). e00467–e00467. 7 indexed citations

Roeloffs, Rosemarie, Alan D. Wickenden, Christopher Crean, et al.. (2008). In Vivo Profile of ICA-27243 [N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a Potent and Selective KCNQ2/Q3 (Kv7.2/Kv7.3) Activator in Rodent Anticonvulsant Models. Journal of Pharmacology and Experimental Therapeutics. 326(3). 818–828. 54 indexed citations

Wickenden, Alan D., Barry London, P. Kay Wagoner, et al.. (2007). N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): A Novel, Selective KCNQ2/Q3 Potassium Channel Activator. Molecular Pharmacology. 73(3). 977–986. 99 indexed citations

Wickenden, Alan D., Rosemarie Roeloffs, Grant McNaughton‐Smith, & Greg C. Rigdon. (2004). KCNQ potassium channels: drug targets for the treatment of epilepsy and pain. Expert Opinion on Therapeutic Patents. 14(4). 457–469. 7 indexed citations

Musso, David L., Felicia R. Cochran, James L. Kelley, et al.. (2002). Indanylidenes. 1. Design and Synthesis of (E)-2-(4,6-Difluoro-1-indanylidene)acetamide, a Potent, Centrally Acting Muscle Relaxant with Antiinflammatory and Analgesic Activity. Journal of Medicinal Chemistry. 46(3). 399–408. 55 indexed citations

White, Helen L., Thomas E. Johnson, Stacey A. Jones, et al.. (1998). Biochemical and pharmacologic properties of 2614W94, a reversible, competitive inhibitor of monoamine oxidase-A. Drug Development Research. 45(1). 1–9. 1 indexed citations

Rigdon, Greg C.. (1996). 1192U90 in Animal Tests That Predict Antipsychotic Efficacy, Anxiolysis, and Extrapyramidal Side Effects. Neuropsychopharmacology. 15(3). 231–242. 11 indexed citations

10.

Durcan, Michael J., Greg C. Rigdon, Mark H. Norman, & Philip F. Morgan. (1995). Is clozapine selective for the dopamine D4 receptor?. Life Sciences. 57(18). PL275–PL283. 17 indexed citations

11.

Ferris, R M, Lawrence E. Brieaddy, Nariman B. Mehta, et al.. (1995). Pharmacological Properties of 403U76, a New Chemical Class of 5-Hydroxytryptamine- and Noradrenaline-reuptake Inhibitor. Journal of Pharmacy and Pharmacology. 47(9). 775–781. 33 indexed citations

12.

Norman, Mark H., Greg C. Rigdon, Frank Navas, & Barrett R. Cooper. (1994). Cyclic Benzamides as Mixed Dopamine D2/Serotonin 5-HT2 Receptor Antagonists: Potential Atypical Antipsychotic Agents. Journal of Medicinal Chemistry. 37(16). 2552–2563. 61 indexed citations

13.

Chang, K J, et al.. (1993). A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86.. Journal of Pharmacology and Experimental Therapeutics. 267(2). 852–857. 132 indexed citations

14.

Rigdon, Greg C., et al.. (1992). 5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex.. Journal of Pharmacology and Experimental Therapeutics. 263(2). 486–493. 114 indexed citations

15.

Pirch, James H., et al.. (1991). Basal Forebrain Modulation of Cortical Cell Activity During Conditioning. Advances in experimental medicine and biology. 295. 219–231. 20 indexed citations

16.

White, Helen L., et al.. (1991). Biochemical and pharmacological properties of BW 1370U87 — a novel, selective monoamine oxidase A inhibitor. European Neuropsychopharmacology. 1(3). 315–317. 1 indexed citations

17.

Rigdon, Greg C.. (1990). Differential effects of apomorphine on prepulse inhibition of acoustic startle reflex in two rat strains. Psychopharmacology. 102(3). 419–421. 78 indexed citations

18.

Rigdon, Greg C., William K. Boyes, & Robert S. Dyer. (1989). Effect of perinatal monosodium glutamate administration on visual evoked potentials of juvenile and adult rats. Neurotoxicology and Teratology. 11(2). 121–128. 9 indexed citations

19.

Rigdon, Greg C., et al.. (1988). Ketamine alters rat flash evoked potentials. Pharmacology Biochemistry and Behavior. 30(2). 421–426. 17 indexed citations

20.

Dyer, Robert S. & Greg C. Rigdon. (1987). Urethane affects the rat visual system at subanesthetic doses. Physiology & Behavior. 41(4). 327–330. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact